Nilotinib impairs skeletal myogenesis by increasing myoblast proliferation

Abstract Background Tyrosine kinase inhibitors (TKIs) are effective therapies with demonstrated antineoplastic activity. Nilotinib is a second-generation FDA-approved TKI designed to overcome Imatinib resistance and intolerance in patients with chronic myelogenous leukemia (CML). Interestingly, TKIs...

Full description

Bibliographic Details
Main Authors: Osvaldo Contreras, Maximiliano Villarreal, Enrique Brandan
Format: Article
Published: BMC 2018-02-01
Series:Skeletal Muscle
Online Access: